BR9914848A - Composição e processo para o tratamento de distúrbios da retina externa - Google Patents

Composição e processo para o tratamento de distúrbios da retina externa

Info

Publication number
BR9914848A
BR9914848A BR9914848-0A BR9914848A BR9914848A BR 9914848 A BR9914848 A BR 9914848A BR 9914848 A BR9914848 A BR 9914848A BR 9914848 A BR9914848 A BR 9914848A
Authority
BR
Brazil
Prior art keywords
treatment
composition
disorders
external retina
external
Prior art date
Application number
BR9914848-0A
Other languages
English (en)
Inventor
Robert J Collier Jr
Mark R Hellberg
Michael A Kapin
George E Barnes
Michael L Chandler
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of BR9914848A publication Critical patent/BR9914848A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSIçãO E PROCESSO PARA O TRATAMENTO DE DISTúRBIOS DA RETINA EXTERNA" Composições e processos para o tratamento de distúrbios da retina externa com antagonistas de glutamato são descritos.
BR9914848-0A 1998-10-27 1999-10-20 Composição e processo para o tratamento de distúrbios da retina externa BR9914848A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10571298P 1998-10-27 1998-10-27
PCT/US1999/024502 WO2000024396A1 (en) 1998-10-27 1999-10-20 Treatment of disorders of the outer retina

Publications (1)

Publication Number Publication Date
BR9914848A true BR9914848A (pt) 2001-07-10

Family

ID=22307389

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914848-0A BR9914848A (pt) 1998-10-27 1999-10-20 Composição e processo para o tratamento de distúrbios da retina externa

Country Status (12)

Country Link
US (1) US6509355B1 (pt)
EP (1) EP1126850A4 (pt)
JP (1) JP2002528416A (pt)
KR (1) KR20020002356A (pt)
CN (1) CN1324240A (pt)
AR (1) AR023687A1 (pt)
AU (1) AU761824B2 (pt)
BR (1) BR9914848A (pt)
CA (1) CA2347863C (pt)
TR (1) TR200101149T2 (pt)
WO (1) WO2000024396A1 (pt)
ZA (1) ZA200103236B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050283109A1 (en) * 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US7220224B1 (en) * 2003-03-07 2007-05-22 Minu, Llc Retinal translocation and fixation using adhesive material
US20050130878A1 (en) * 2003-11-26 2005-06-16 Alcon, Inc. Prevention of photic injury by administering a TACE inhibitor
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2008098027A2 (en) * 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2717080B1 (fr) 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TR199800407T1 (xx) 1995-09-08 1998-05-21 Synthelabo 4-(Sikloalkil) piperidin ve t�revleri, haz�rlan��lar�, tedavi ama�l� kullan�mlar�.
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
CA2241913A1 (en) * 1996-01-02 1997-07-10 Synthelabo Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy

Also Published As

Publication number Publication date
AU761824B2 (en) 2003-06-12
US6509355B1 (en) 2003-01-21
KR20020002356A (ko) 2002-01-09
AU1516900A (en) 2000-05-15
EP1126850A4 (en) 2003-01-15
CA2347863A1 (en) 2000-05-04
CN1324240A (zh) 2001-11-28
WO2000024396A9 (en) 2000-09-28
AR023687A1 (es) 2002-09-04
WO2000024396A1 (en) 2000-05-04
ZA200103236B (en) 2001-10-23
EP1126850A1 (en) 2001-08-29
JP2002528416A (ja) 2002-09-03
TR200101149T2 (tr) 2001-10-22
CA2347863C (en) 2009-05-05

Similar Documents

Publication Publication Date Title
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
ATE253063T1 (de) 5-ht1f-agonisten
DK0751939T5 (da) Naphthylamider som centralnervesystemmidler
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
BR9914158A (pt) Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
CA2347863A1 (en) Treatment of disorders of the outer retina
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]